ClinicalTrials.gg
RecruitingNCT06245434COMARHYTHMUpdated Jul 30, 2026

Circadian Rhythmicity During Coma Awakening

An interventional study of Repeated behavioural assessment and Act-Pass paradigm in Acute Brain Injury Coma, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
17 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Brain Injuries with a site in France — 18 open to participants now, 19 under way, none of them phase 3. Brain Injuries · France.

Planned enrollment
14th of 36
90 · median 46
Started
2024
with 3 others
No phase
26 of 72
6 open now
Primary completion
2029-06
later than 15 of 18 live
Registered
58th of 72
by date
Lead sponsor
4 of 72
Hospices Civils de Lyon

Among the 72 studies in Brain Injuries with a site in France, this one is the 14th largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2024, is one of 26 with no phase, reaches primary completion later than 15 of the 18 other live ones, and was the 58th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

18 of the 72 studies in Brain Injuries with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 17 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Brain Injuries with a site in France, or all of them as a file.
02

Study summary

Acute brain injury is a major cause of admission to intensive care units, as well as of mortality and morbidity, worldwide and for all age groups. With most patients surviving these injuries thanks to recent medical advances, society is facing not only the growing burden of disability, but above all the ethical issues involved in withdrawal of life-sustaining therapies (WSLT). To resolve this dilemma, effective treatment would be necessary, but this is hampered by our limited knowledge of the pathophysiological mechanisms of the natural history of coma, from onset to recovery. A more systematic description of coma awakening using a multimodal battery in intensive care unit patients would enable us to refine the awakening and re-emergence of consciousness and define appropriate biomarkers for selecting candidates in interventional studies.

The investigators hypothesize that the current postulate of successive stages (i.e. from one clinical class to the next) of coma recovery is incomplete, as it does not take into account the rhythmic nature of wakefulness. The investigators propose that the best correlate of the natural history of coma recovery is a gradual shift from the loss of physiological cycles to a circadian rhythmicity of arousal indices (behavioural and neurophysiological) and a wide amplitude of metric fluctuations in assessing content richness.

03

Conditions studied

  • Acute Brain Injury Coma

Keywords

  • Circadian rhythms
  • Consciousness
  • Wakefulness
  • Biomarkers
  • Monoamines
04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group 1

  • Admission to the Neurological Intensive Care Unit
  • Initial disorder of consciousness (GCS \< 8) or initial brain lesion (on CT or MRI) requiring intubation and sedation during management (for upper airway protection or due to coma)
  • Intubated patient under mechanical ventilation with no response to simple commands
  • Weaning from sedation : acquired / possible within 7 days of inclusion in the absence of new complications
  • Severity of clinical or morphological impairment leading to risk of persistent disturbance of consciousness
  • Sedation discontinued or able to be discontinued within 3 month of initial management of the disorder of consciousness or brain injury
  • Effective treatment of the cause of admission without risk of short-term recurrence
  • Patient aged 17 or over
  • Urinary catheter in place at the time of inclusion and to remain in place until Visit N°1
  • Presence of relatives able to sign consent or of the minor's legal representative

Group 2

  • Admission to the Neurological Intensive Care Unit or the Neurological Continuing Care Unit
  • Absence of severe disorder of consciousness but possibility of minimal alteration of the initial Glasgow score (GCS between 9 and 15) with no time limit, with a stratification of three consecutive patient populations distinguished by the initial neurological alteration:

    • GCS = 15
    • GCS \< 15 by predominance of an initial defect in responses to simple or complex commands obtained by motor or verbal means, without abnormality of arousal (E score = 4 but M score \< 6 and/or V score \< 5)
    • GCS \< 15 with predominant initial somnolence, with or without abnormal motor or verbal responses to simple or complex commands (E score = 2 or 3 but M score = 6 and/or V score = 5).
  • Existence of functional communication or functional use of objects at inclusion
  • Mechanism of injury for which the aetiology is no longer active or at risk of recurrence
  • Patient aged 17 or over
  • Urinary catheter in place at the time of inclusion and to remain in place until Visit N°1
  • In the case of impaired judgement despite functional communication or in the case of aphasia with functional use of objects: presence of relatives able to sign consent or of the legal representative of the minor or of the legal representative of the protected adult.

Group 3

  • Admission to the Adult Post-Resuscitation Rehabilitation Department, in the Neurological Multidisciplinary Intensive Care Unit
  • Disturbance of consciousness defined by an absence of communication or an absence of functional use of objects (for patients with aphasia), i.e. the two signs that could indicate emergence from the pauci-relational state, which includes patients presenting :

    • persistent coma
    • a vegetative state (or unresponsive wakefulness syndrome)
    • a pauci-relational state (MCS- or MCS+ if responding to simple commands).
  • Persistent within the following timeframe

    • More than 3 months after the initial management of the disorder of consciousness or brain injury
    • More than 1 month after a post-anoxic coma.
  • Mechanism of injury for which the aetiology is no longer active or at risk of recurrence
  • Patient aged 17 or over
  • Presence of relatives likely to sign the consent or of the legal representative of a minor or of the legal representative of a protected adult

Exclusion criteria

Exclusion Criteria:

Group 1

  • Subjects with a to MRI scans
  • Admission for status epilepticus
  • Existence of status epilepticus during the stay and persisting for > 24h or presenting an electrical remission for less than 48h prior to inclusion
  • Post-anoxic coma with bilateral abolition of N20 PES cortical responses
  • Coma related to a potentially recurrent cause of coma (tumours, infectious diseases with risk of relapse and inflammatory diseases)
  • Moribund patient ( \< 24h) or in WLST (no assessment possible of the dynamics of ongoing awakening)
  • Haemodynamic or respiratory instability incompatible with a prolonged attempt to stop sedation (except in the case of scheduled surgery outside the visit dates)
  • Patients under guardianship, curatorship or safeguard of justice
  • Patients not affiliated to the French health insurance system
  • Pregnant women or women of childbearing age without proof of the absence of a current pregnancy

Group 2

  • Subjects with a contraindication to MRI scans
  • Epileptic seizures on admission or during the stay

    • Single seizure: if no rapid return to consciousness (GCS \< 8 for > 12 hours)
    • > 2 distinct epileptic seizures regardless of the duration of loss of consciousness
    • Status epilepticus
  • Post-anoxic coma with bilateral abolition of N20 cortical PES responses.
  • Coma linked to a potentially recurrent cause of coma (tumour, infection with risk of relapse and inflammation).
  • A moribund patient (life expectancy \< 24 hours) or a patient undergoing WLST with a high risk of death before the end of the study (inclusion possible if no therapeutic escalation is decided in a stabilised patient).
  • Haemodynamic or respiratory instability incompatible with prolonged evaluation of the absence of sedation (risk of general anaesthesia for further failure, except in the case of scheduled surgery outside the visit dates).
  • Patients under guardianship, curatorship or safeguard of justice
  • Patients not affiliated to the French health insurance system
  • Pregnant women or women of childbearing age without proof of the absence of a current pregnancy

Group 3

  • Subjects with a contraindication to MRI scans
  • Epileptic seizures during the week preceding inclusion:

    • Single seizure: if no rapid return to usual state of consciousness for > 12 hours
    • > 2 separate comitial seizures regardless of duration of loss of consciousness
    • Epileptic malaise
  • Post-anoxic coma with bilateral abolition of N20 cortical responses to SEP
  • Coma related to a potentially recurrent cause of coma (tumour, infection with risk of relapse and inflammation)
  • Moribund patients (life expectancy \< 24 hours) or patients undergoing WSLT with a high risk of death before the end of the study (inclusion possible if no therapeutic escalation is decided in a stabilised patient).
  • Haemodynamic or respiratory instability incompatible with prolonged evaluation of the absence of sedation (risk of general anaesthesia for further failure, except in the case of scheduled surgery outside the visit dates).
  • Patients under guardianship, curatorship or safeguard of justice prior to the event that provoked their state of chronic disturbance of consciousness. Patients under guardianship because of their chronic disorder of consciousness are eligible for the study.
  • Patients not affiliated to the French health insurance system
  • Pregnant women or women of childbearing age without proof of the absence of a current pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Main group with acute brain injury and initial Disorders of consciousness

    50 patients in the initial phase of acute brain injury with disturbed consciousness, hospitalized in the Neurological Intensive Care Unit and at risk of delayed awakening

    Behavioral: Repeated behavioural assessment · Behavioral: Act-Pass paradigm · Behavioral: Biological measures of circadian and monoamines biomarkers · Behavioral: Transcriptomic and genomic analysis · Behavioral: Polysomnography with concomitant environment recording · Behavioral: Actimetry · Behavioral: Morphological MRI · Behavioral: Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.

  • Active comparator
    Comparative group with acute brain injury without Disorders of consciousness

    20 patients in the initial phase of brain damage WITHOUT disturbance of consciousness, hospitalized in the Neurological Intensive Care Unit and presenting similar causes of brain damage.

    Behavioral: Repeated behavioural assessment · Behavioral: Act-Pass paradigm · Behavioral: Biological measures of circadian and monoamines biomarkers · Behavioral: Transcriptomic and genomic analysis · Behavioral: Polysomnography with concomitant environment recording · Behavioral: Actimetry · Behavioral: Morphological MRI · Behavioral: Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.

  • Active comparator
    Comparative group with post-acute Disorders of consciousness

    20 patients in the sub-acute or chronic phase of a consciousness disorder and admitted to the Post-Resuscitation Rehabilitation Service.

    Behavioral: Repeated behavioural assessment · Behavioral: Act-Pass paradigm · Behavioral: Biological measures of circadian and monoamines biomarkers · Behavioral: Transcriptomic and genomic analysis · Behavioral: Polysomnography with concomitant environment recording · Behavioral: Actimetry · Behavioral: Morphological MRI · Behavioral: Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.

Interventions

  • BehavioralRepeated behavioural assessment

    One CRS-R per visit * 4 SECONDs * Eye tracking during every clinical assessment * Recording every 2-4h of the Glasgow Coma Score * Recording every 2h of the temperature and pupillometer reactivity to light

  • BehavioralAct-Pass paradigm

    Before and after sedation withdrawal Assessment of infra-clinical response to an active paradigm (attention focalisation or diversion).

  • BehavioralBiological measures of circadian and monoamines biomarkers

    Systematic urinary sampling every 2 hours for melatonin, cortisol and monoamines metabolites

  • BehavioralTranscriptomic and genomic analysis

    Definition of the peripheral cellular clock by 2 transcriptomic measures Constitution of a genomic biobank to analyse the cofounding factors for circadian disruption and differential clinical recovery

  • BehavioralPolysomnography with concomitant environment recording

    One 48h polysomnography for the first visit \+ 3\* 24h polysomnography for each visit Synchronised recordings of light, sound, activity in patients' rooms

  • BehavioralActimetry

    Continuous recording of movements at the wrist during 7 days after sedation withdrawal

  • BehavioralMorphological MRI

    Precise description of brain lesion by a 3T MRI within the 1st week after sedation withdrawal

  • BehavioralAssessment of correlation between patients' behaviour and neurophysiological markers of consciousness.

    Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.

06

What researchers measure

Primary outcomes

  1. Consciousness outcome

    Coma Recovery Scale - revised used to define 4 possible consciousness outcomes (the best observed before death if the patient died at the date of assessment): * Coma * Unresponsive Wakefulness Syndrome * Minimally Conscious State * Exit-Minimally Conscious State (conscious patient)

    Time frame: 2, 3, 4,6 months post injury

Secondary outcomes

  1. Functional outcome

    Glasgow Outcome Scale (GOS) Glasgow Outcome Scale Extended (GOSE) Minimum score 1 and maximum score 5. The lowest score is 5.

    Time frame: GOS: 2, 3, 4,6 months post injury GOSE: 6 months post injury

  2. Cognitive outcome

    MOCA scale The MOCA is a short 30-question test that assesses several cognitive domains and allows for early detection of cognitive disorders. The MOCA test takes about 10-15 minutes to administer and consists of several sections, the first of which is an assessment of orientation in time and space. Then there are tasks that assess memory, concentration and reasoning ability, as well as language and visuospatial ability tasks. The MOCA score can range from 0 to 30 points, with a score of 26 points or more considered normal.

    Time frame: 6 months post injury

  3. Quality of life outcome SF-36 scale

    At the end, a score for each dimension of the SF-36 was calculated, ranging from 0 to 100. A low score reflects a perception of poor health, loss of function, presence of pain. A high score reflects a perception of good health, absence of functional deficit, and pain (3,6,7)

    Time frame: 6 months post injury

07

Study locations

1 of 1 sites recruiting
  • Service de Réanimation Polyvalente Neurologique Hôpital Neurologique Pierre Wertheimer
    Bron, Lyon 69500, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2029, 54 months after the start.

Of 285 non-industry interventional studies with no phase under Brain Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 54 months is above that.

Counting every sponsor, half of 298 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 7, 2024
StartActual
Dec 2, 2024
Primary completionEst.
Jun 2, 2029
CompletionEst.
Jun 2, 2029
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06245434
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Dec 2, 2024
Primary completion
Jun 2, 2029 (estimated)
Completion
Jun 2, 2029 (estimated)
Last update
Jul 30, 2026

Study contacts

GOBERT FLORENT, M.D. Ph.D.
Contact
florent.gobert01@chu-lyon.fr
0472681296 ext. +33
GOBERT FLORENT, M.D. Ph.D.
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion